Karl Pfleger Explains the Aging Biotech Explosion

On this episode of Longevity by Design, Dr. Gil Blander sits down with Dr. Karl Pfleger, aging biotechnology investor and creator of AgingBiotech.info, to dissect the rapidly evolving field of aging therapeutics. Karl breaks down the sector into two main categories: interventions that slow aging rates versus rejuvenation strategies that repair accumulated damage.Karl highlights the most promising areas in his investment portfolio, including senolytics for clearing senescent cells and epigenetic reprogramming technologies. He explains why current aging clocks aren't ready for clinical use and discusses the limitations of popular interventions like GLP-1 drugs and fasting protocols. The conversation reveals that 14 Phase 3 clinical trials are currently testing core aging therapeutics.The discussion covers recent FDA approvals for ATTR treatments and stem cell therapies, signaling the field's maturation. Karl emphasizes that meaningful life extension requires a "divide and conquer" strategy, targeting multiple aging mechanisms simultaneously rather than relying on single interventions. Despite exciting therapeutic developments, he maintains that optimizing diet, exercise, and sleep remains the most impactful strategy for extending healthspan today.Guest-at-a-Glance💡 Name: Dr. Karl Pfleger💡 What they do: Angel investor, philanthropist, and advocate in aging and longevity biotechnology💡 Institution(s): Creator and maintainer of AgingBiotech.info (comprehensive public database of 400+ aging companies)💡 Noteworthy: Exclusively invests in aging/longevity sector with 15+ portfolio companies targeting damage repair approaches💡 Where to find them: LinkedIn | AgingBiotech.info | X (Twitter)Episode highlights:00:00:00 Introduction to GLP-1 Drugs and Their Impact00:00:56 Meet Dr. Karl Pfleger: A Pioneer in Aging and Longevity00:02:50 Karl Pfleger's Journey from Tech to Aging Biology00:05:18 The Current State of Longevity Biotech00:09:47 Exciting Developments in Rejuvenation Biotechnology00:24:17 Aging Biotech Info: A Comprehensive Resource00:31:59 Future Plans for Aging Biotech Info00:36:51 The Obesity Revolution: GLP-1 Receptor Agonists00:40:29 Global Obesity Rates and GLP-1 Drugs00:40:43 Potential Benefits and Limitations of GLP-1 Drugs00:42:13 Muscle Atrophy and Side Effects of GLP-1 Drugs00:44:12 Emerging Muscle Aging Treatments00:46:10 Biotech Companies and Obesity Programs00:46:53 Public vs. Private Biotech Companies00:49:12 Fasting and Calorie Restriction00:55:20 Blood Transfusions and Parabiosis00:58:09 Metformin and N-of-1 Experiments00:59:13 Comprehensive Aging Interventions01:03:54 Diagnostics and Aging Clocks01:13:49 Future of Aging Interventions01:16:07 Top Tips for Health and LongevityWe Appreciate You!As a token of our gratitude, we’re excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcastFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast